Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.

MLA

Nosadini, Margherita, et al. “Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-Analysis.” JAMA Neurology, vol. 78, no. 11, Nov. 2021, pp. 1333–44. EBSCOhost, https://doi.org/10.1001/jamaneurol.2021.3188.

APA

Nosadini, M., Eyre, M., Molteni, E., Thomas, T., Irani, S. R., Dalmau, J., Dale, R. C., Lim, M., Anlar, B., Armangue, T., Benseler, S., Cellucci, T., Deiva, K., Gallentine, W., Gombolay, G., Gorman, M. P., Hacohen, Y., Jiang, Y., Lim, B. C., & Muscal, E. (2021). Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurology, 78(11), 1333–1344. https://doi.org/10.1001/jamaneurol.2021.3188

Chicago

Nosadini, Margherita, Michael Eyre, Erika Molteni, Terrence Thomas, Sarosh R. Irani, Josep Dalmau, Russell C. Dale, et al. 2021. “Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-Analysis.” JAMA Neurology 78 (11): 1333–44. doi:10.1001/jamaneurol.2021.3188.